Cargando…

Current usage of tumor treating fields for glioblastoma

BACKGROUND: Tumor Treating Fields (TTF) have entered clinical practice for newly diagnosed and recurrent glioblastoma (GGM). However, controversies remain unresolved with regard to appropriate usage. We sought to determine TTF usage in major academic neuro-oncology programs in New York City, USA and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lassman, Andrew B, Joanta-Gomez, Adela E, Pan, Peter C, Wick, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7345837/ https://www.ncbi.nlm.nih.gov/pubmed/32666048 http://dx.doi.org/10.1093/noajnl/vdaa069

Ejemplares similares

Determinants of tumor treating field usage in patients with primary glioblastoma: A single institutional experience
por: Ballo, Matthew T, et al.
Publicado: (2022)

OptimalTTF-1: Enhancing tumor treating fields therapy with skull remodeling surgery. A clinical phase I trial in adult recurrent glioblastoma
por: Korshoej, Anders Rosendal, et al.
Publicado: (2020)

Assessing the added value of apparent diffusion coefficient, cerebral blood volume, and radiomic magnetic resonance features for differentiation of pseudoprogression versus true tumor progression in patients with glioblastoma
por: Leone, Riccardo, et al.
Publicado: (2023)

Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
por: Han, Kelong, et al.
Publicado: (2014)

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial
por: Lassman, Andrew B, et al.
Publicado: (2022)

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial
por: Lassman, Andrew B, et al.
Publicado: (2019)

Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields
por: Pandey, Manjari, et al.
Publicado: (2022)

Lung toxicity of lomustine in the treatment of progressive gliomas
por: Seliger, Corinna, et al.
Publicado: (2022)

Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma
por: Carneiro, Benedito A, et al.
Publicado: (2022)

Analysis of physical characteristics of Tumor Treating Fields for human glioblastoma
por: Lok, Edwin, et al.
Publicado: (2017)

Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival
por: Hu, Leland S., et al.
Publicado: (2012)

Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG08.02) randomized clinical trial
por: Song, Andrew J, et al.
Publicado: (2021)

The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab
por: Gahrmann, Renske, et al.
Publicado: (2022)

Tumor treating fields for the treatment of glioblastoma: Current understanding and future perspectives
por: Colamaria, Antonio, et al.
Publicado: (2023)

Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy
por: Eoli, Marica, et al.
Publicado: (2019)

Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas: A Retrospective Observational Study
por: Barbaro, Marissa, et al.
Publicado: (2022)

Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825
por: Scheurer, Michael E, et al.
Publicado: (2022)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

Finite element analysis of Tumor Treating Fields in a patient with posterior fossa glioblastoma
por: Lok, Edwin, et al.
Publicado: (2020)

Imaging and histopathologic correlates of plasma cell-free DNA concentration and circulating tumor DNA in adult patients with newly diagnosed glioblastoma
por: Nabavizadeh, Seyed Ali, et al.
Publicado: (2020)

SDS2 CHALLENGES IN TREATMENT OF GLIOBLASTOMA: CURRENT CONCEPTS AND THERAPEUTIC PERSPECTIVES
por: Wick, Wolfgang
Publicado: (2019)

Change in volumetric tumor growth rate after cytotoxic therapy is predictive of overall survival in recurrent glioblastoma
por: Oshima, Sonoko, et al.
Publicado: (2023)

Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma
por: Parney, Ian F, et al.
Publicado: (2022)

The Value of Tumor Treating Fields in Glioblastoma
por: Zhang, Chaochao, et al.
Publicado: (2020)

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
por: Lim, Michael, et al.
Publicado: (2022)

Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with (177)Lu-DOTATATE
por: Strosberg, Jonathan R., et al.
Publicado: (2021)

Fluoroscopy usage in contemporary interventional electrophysiology: Insights from a European registry
por: Kosiuk, Jedrzej, et al.
Publicado: (2020)

What is a glioblastoma?
por: Lassman, Andrew B, et al.
Publicado: (2023)

Multivariate analysis of associations between clinical sequencing and outcome in glioblastoma
por: Yang, Peter H, et al.
Publicado: (2022)

Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma
por: Schmidt, Teresa, et al.
Publicado: (2023)

Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
por: de Groot, John F, et al.
Publicado: (2022)

P53-negative status and gross total resection as predictive factors for autologous tumor vaccine treatment in newly diagnosed glioblastoma patients
por: Yamada, Erika, et al.
Publicado: (2023)

Impact of race on care, readmissions, and survival for patients with glioblastoma: an analysis of the National Cancer Database
por: Hodges, Tiffany R, et al.
Publicado: (2021)

Timing of glioblastoma surgery and patient outcomes: a multicenter cohort study
por: Müller, Domenique M J, et al.
Publicado: (2021)

Temozolomide chronotherapy in patients with glioblastoma: a retrospective single-institute study
por: Damato, Anna R, et al.
Publicado: (2021)

Predictors of survival in elderly patients undergoing surgery for glioblastoma
por: Voisin, Mathew R, et al.
Publicado: (2021)

Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2021)

Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial
por: Griguer, Corinne E, et al.
Publicado: (2021)

A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma
por: Ramesh, Karthik, et al.
Publicado: (2022)

Human cytomegalovirus seropositivity is associated with decreased survival in glioblastoma patients
por: Foster, Haidn, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bmbv738am3sflm3ljl5ojp0nde